Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a Healthcare company (Biotechnology) with a market capitalization of $7.2B. The Maz Rating grades it against the other companies in its sector.
Axsome Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $137.01, Axsome Therapeutics, Inc. trades at 8.3x sales and 68.2x book value. Over the last twelve months it generated about $865M of revenue and a net loss of $161M. It runs a gross margin of 93.2%, an operating margin of -17.7% and a net margin of -18.2%. It shows return on equity of -189.7%, return on invested capital of -39.6% and a free cash flow yield of -1.1%. On the balance sheet: a debt-to-equity ratio of 2.07 and a current ratio of 1.42. Over the past 52 weeks the share price ranged from $123.00 to $260.19, with a beta of 0.60.
Axsome Therapeutics, Inc. does not currently pay a dividend.
27 Wall Street analyst ratings cover the stock: 26 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Axsome Therapeutics, Inc. (AXSM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.37% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.40% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.37% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.40% / 33% · Receivables / Mkt Cap (36m) 3.72% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 2.37% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.40% / 33.33% · Receivables / Mkt Cap (24m) 3.72% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 28.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 42.2% / 33.33% · Receivables / Avg Assets (4Q) 36.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 26.4% / 33.33% · (Cash+ST Inv) / Total Assets 38.0% / 33.33% · (Cash+Recv) / Total Assets 79.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Axsome Therapeutics, Inc. (AXSM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Axsome Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Axsome Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.